WO2004084865A1 - Formulations comprising an active ingredient and cocoa powder and use thereof - Google Patents

Formulations comprising an active ingredient and cocoa powder and use thereof Download PDF

Info

Publication number
WO2004084865A1
WO2004084865A1 PCT/IB2004/000860 IB2004000860W WO2004084865A1 WO 2004084865 A1 WO2004084865 A1 WO 2004084865A1 IB 2004000860 W IB2004000860 W IB 2004000860W WO 2004084865 A1 WO2004084865 A1 WO 2004084865A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation according
oil
apis
chosen
administration
Prior art date
Application number
PCT/IB2004/000860
Other languages
English (en)
French (fr)
Inventor
Nils-Olof Lindberg
Katarina Eva Anette Lindell
Alice C. Martino
Fredrik Per Nicklasson
Kristina Maarit Thyresson
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Priority to CA002519155A priority Critical patent/CA2519155A1/en
Priority to MXPA05010196A priority patent/MXPA05010196A/es
Priority to AU2004224557A priority patent/AU2004224557B2/en
Priority to EP04720946A priority patent/EP1605921A1/en
Priority to BRPI0408655-4A priority patent/BRPI0408655A/pt
Priority to JP2006506377A priority patent/JP2006521348A/ja
Publication of WO2004084865A1 publication Critical patent/WO2004084865A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • This invention relates to novel orally administered pharmaceutical formulations of one or more active pharmaceutical ingredients (APIs), optionally comprising salts, 5 complexes, prodrugs and metabolites thereof, further comprising cocoa powder, to the use of one or more active pharmaceutical ingredients (APIs), optionally comprising salts, prodrugs and metabolites thereof, for the manufacturing of a medicament to be administered orally for achieving a pharmacological effect, and to methods of medical treatment of humans or animals by oral administration of one or more active pharma- 10 ceutical ingredients (APIs), optionally comprising salts, prodrugs and metabolites thereof.
  • APIs active pharmaceutical ingredients
  • APIs active pharmaceutical ingredients
  • APIs active pharmaceutical ingredients
  • the present invention provides an orally administered pharmaceutical formulation of one or more APIs, optionally comprising salts, complexes, prodrugs and metabo- lites thereof for achieving a pharmacological effect.
  • the administration can be to a human being or to an animal.
  • Rapid onset is herein meant that a therapeutic effect is achieved within a short period of time, preferably in less than 1 hour, more preferably in less than 30 minutes, following administration.
  • the administration may be accomplished without the addition of liquid.
  • Administration without added liquid is a big advantage in all those situations where e g clean water or other suitable liquid is not available, such as on travel.
  • the administration is discreet being a big advantage e g at lectures and on the theatre.
  • use of the present formulation, which should melt in the mouth rather than be swallowed is of a great advantage to all those persons having difficulties in swallowing a traditional tablet.
  • a particularly useful dosage form of the present invention is thus a formulation that disintegrates or melts in the mouth without need for drinking water or other fluid.
  • the formulation is a dosage form comprising a therapeutically effective amount of one or more APIs. It is preferred that the amount of the one or more APIs be lower than an amount causing significant side effects.
  • An object of the invention is to provide novel orally administered pharmaceutical formulations of one or more APIs comprising cocoa powder.
  • a second object of the invention is to provide methods for preparing said formulations.
  • a t hird object of the invention is methods for using said formulations in therapy for medical treatment of a human or animal subject.
  • Formulations according to the present invention should preferably melt in the oral cavity, whereby intraoral uptake of the one or more APIs is favorized.
  • the invention is adapted for discreet self-administration.
  • discreet self- administration herein is meant self-administration that does not draw attention to the existence of a need for therapy.
  • the formulation provides for a rapid onset through essentially intraoral uptake of the one or more APIs; 2) The formulation does not require any added liquid at the time of administration;
  • the formulation provides for discreet self-administration; 6) The formulation is easy to administer for persons having problems in swallowing;
  • the formulation provides for increased bioavailability due to reduced first-pass metabolism
  • the formulation may provide for an association of pleasure.
  • Cocoa powder is defined as cocoa nib with some fat removed and ground into a powder. Cocoa nib is defined as cocoa beans with the shell removed. Cocoa butter is defined as fat expelled from the center (kernels or nib) of cocoa beans. Cocoa powder is prepared from roasted cocoa beans. It is a complex compound, which consists of starch, cocoa butter, amino acids, proteins, xanthines, amines, mono- and polysaccharides % phospholipids, flavonoids, pyrazines, etc.
  • the object of the invention to provide such a formulation that disintegrates and/or melts in the oral cavity with or without the aid of salivary fluid or mechanical erosion, or a combination thereof after which the formulation may show adhesiveness towards the tissues in the oral cavity.
  • buffering agents provides for a transient change in local pH of the saliva, which facilitates uptake in the oral cavity.
  • cocoa powder acts as taste masker, filler and texturizer.
  • a general embodiment of a formulation according to the present invention has a weight of around 200 - 1000 mg and has the following composition (w/w):
  • a formulation weighing around 400 mg, is prepared having the following composition (w/w):
  • Cocoa powder may be used in a non-alkalized form and in an alkalized form. Both are useful in the present formulations. Alkalized cocoa powder is preferred when a somewhat milder taste is desirable.
  • a part of the hydrogenated soybean oil is melted.
  • the solid components i e the API if solid (eletriptan hydrobromide is solid), cocoa powder, mannitol, maize starch, aspartame, acesulfame-K, titanium dioxide, sodium chloride and the flavoring agents if solid, are added and mixed.
  • a reduction of particle size of the solid components is performed by milling in a roll-refiner. If the solid components have already got the required particle size, e g by milling before the mixing with the fatty components, roll refining is dispensed with.
  • the mixture After treatment in the roll-refiner the mixture is mixed with the rest of the melted fatty components or remelted, if solidified, and mixed with the rest of t he melted hydrogenated soybean oil.
  • a mixing of the melt is performed in a suitable mixer.
  • the liquid components, i e the API if liquid (eletriptan hydrobromide is though solid and is handled as above), soy lecithin and the flavoring agents if liquid, are added. Tablets or other solid dosage forms are subsequently made using suitable techniques, such as molding, extrusion or congealing, including pastiUation, when necessary after suitable preconditioning. Also other suitable manufacturing methods may be used.
  • Example 2 In essentially the same way as in Example 1 is manufactured a formulation with a weight of around 500 mg having the below ingredients (w/w):
  • Example 2 In essentially the same way as in Example 1 is manufactured a formulation with a weight of around 300 mg having the below ingredients (w/w):
  • Example 2 In essentially the same way as in Example 1 is manufactured a formulation with a weight of around 400 mg having the below ingredients (w/w):
  • Example 2 In essentially the same way as in Example 1 is manufactured a formulation with a weight of around 600 mg having the below ingredients (w/w):
  • Example 6 Preparation of a further embodiment In essentially the same way as in Example 1 is manufactured a formulation ⁇ vith a weight of around 400 mg having the below ingredients (w/w):
  • Example 2 In essentially the same way as in Example 1 is manufactured a formulation with a weight of around 400 mg having the below ingredients (w/w):
  • Example 8 Preparation of a further embodiment In essentially the same way as in Example 1 is manufactured a formulation with a weight of around 400 mg having the below ingredients (w/w):
  • Example 2 In essentially the same way as in Example 1 is manufactured a formulation with a weight of around 400 mg having the below ingredients (w/w):
  • Example 2 In essentially the same way as in Example 1 is manufactured a formulation with a weight of around 400 mg having the below ingredients (w/w):
  • Example 2 In essentially the same way as in Example 1 is manufactured a formulation with a weight of around 300 mg having the below ingredients (w/w):
  • Example 2 In essentially the same way as in Example 1 is manufactured a formulation with a weight of around 300 mg having the below ingredients (w/w):
  • Example 2 In essentially the same way as in Example 1 is manufactured a formulation with a weight of around 800 mg having the below ingredients (w/w):
  • Example 2 In essentially the same way as in Example 1 is manufactured a formulation with a weight of around 500 mg having the below ingredients (w/w):
  • Example 2 In essentially the same way as in Example 1 is manufactured a formulation with a weight of around 600 mg having the below ingredients (w/w):
  • Example 2 In essentially the same way as in Example 1 is manufactured a formulation with a weight of around 500 mg having the below ingredients (w/w):
  • Example 2 In essentially the same way as in Example 1 are manufactured formulations with a weight from around 200 mg to around 1000 mg having the below ingredients:
  • APIs active pharmaceutical ingredients
  • the above one or more active pharmaceutical ingredients is/are selected from APIs suitable for intraoral uptake, preferred, but non-limiting examples of which are o the antiinflammatory agents diclofenac, ketorolac, indometacin, tornoxicam, piroxicam, tenoxicam, ketoprofen, celecoxib and roficoxib; o the muscle relaxants orphenadrine and baclofen; o the drugs affecting bone mineralization alendronic acid and risedronic acid; o the analgesics propoxyphene, buprenorfin, ketobenidon, hydromorphone, tramadol and morphine o the antimigraine preparations dihydroergotamine, ergotamine, eletriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan; o the anti-Parkinson drags pramipexole, ropinirole and selegiline;
  • cocoa powder may be used in its non-alkalized form, its alkalized form or in a mixture thereof.
  • the diluents may be selected from one or more of the compounds sucrose, fructose, glucose, galactose, lactose, maltose, invert sugar, a pharmaceutically acceptable polyol such as xylitol, sorbitol, maltitol, mannitol, isomalt and glycerol, or polydex- trose, or starch, or any mixture thereof, but only to such an extent that the taste-masking effect of the cocoa-powder remains sufficient.
  • a pharmaceutically acceptable polyol such as xylitol, sorbitol, maltitol, mannitol, isomalt and glycerol, or polydex- trose, or starch, or any mixture thereof, but only to such an extent that the taste-masking effect of the cocoa-powder remains sufficient.
  • the lipid ingredient being fatty components, may be chosen from one or more of the following compounds: - cocoa butter and cocoa butter alternatives, including cocoa butter equivalents
  • CBE cocoa butter substitutes
  • CBR cocoa butter replacers
  • CBI cocoa butter improvers
  • the optional buffering agent s may be selected from one or more of carbonates, bicarbonates, acetates, gluconates, glycerophosphates, phosphates or glycinates of sodium, potassium or ammonium, or mixtures thereof. Most phosphates are though less suitable because their taste usually is disagreeable and difficult to mask. Addition of buffering agents/s may increase the uptake through the mucosa in the oral cavity.
  • the sweetener may selected from one or more artificial sweeteners, such as sucrose, aspartame, acesulfame potassium saccharine, sodium saccharine, cyclamate, glycyrrhizine, thaumatin (talin), sucralose, dihydrochalcone (neohesperidin dihydro- chalcone), alitame, miraculin (miracle fruit), monellin (serendipity berry), stevside and/or salts thereof.
  • artificial sweeteners such as sucrose, aspartame, acesulfame potassium saccharine, sodium saccharine, cyclamate, glycyrrhizine, thaumatin (talin), sucralose, dihydrochalcone (neohesperidin dihydro- chalcone), alitame, miraculin (miracle fruit), monellin (serendipity berry), stevside and/or salts thereof
  • the emulsifier/solubiliser is preferably soy lecithin and/or egg lecithin, but may be exchanged for
  • nonionic surfactant such as poloxamer, polyoxyethylene alkyl ether, polyoxyethylene castor oil derivative, polyoxyethylene sorbitan fatty acid ester, monoglyce- ride, diglyceride and esther thereof, polyoxyethylene stearate, polyglycerolester of fatty acids, including polyglycerolpolyricinoleic acid (PGPR), sorbitan fatty acid ester,
  • PGPR polyglycerolpolyricinoleic acid
  • an anionic surfactant such as fatty acid, soap of fatty acid, lactylate, especially sodium and/or calcium stearoyllactylate, sodium lauryl sulfate and latanol,
  • zwitterionic surfactant such as zwitterionic phospholipid, such as phosphati- dylcholine and phosphatidylethanolamine, or mixtures, fractions or derivatives thereof or with lecithin.
  • the taste modifier is preferably selected from sodium chloride, monosodium glutamate and ammonium glycyrrhizinate.
  • the coloring agent is preferably selected from titanium dioxide, iron oxides and aluminum lakes.
  • Formulations according to the present inventions primarily constitute meltable and/or suckable oral tablets, but also include other suitable dosage forms for intraoral administration such as buccal patches, buccal pastes and buccal sprays.
  • the present invention encompasses administration of the captioned formulations via the oral route concomitantly with administration APIs via one or more other routes, such as through transdermal administration, peroral administration, administration by inhalation, administration by creams, salves and vagitories, and/or administration by injection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
PCT/IB2004/000860 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof WO2004084865A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002519155A CA2519155A1 (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof
MXPA05010196A MXPA05010196A (es) 2003-03-26 2004-03-16 Nuevas formulaciones y su uso.
AU2004224557A AU2004224557B2 (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof
EP04720946A EP1605921A1 (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof
BRPI0408655-4A BRPI0408655A (pt) 2003-03-26 2004-03-16 formulações compreendendo um agente ativo e cacau em pó e a sua utilização
JP2006506377A JP2006521348A (ja) 2003-03-26 2004-03-16 活性成分及びカカオ粉末を含む製剤、並びにその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300831-5 2003-03-26
SE0300831A SE0300831D0 (sv) 2003-03-26 2003-03-26 New formulations and use therof

Publications (1)

Publication Number Publication Date
WO2004084865A1 true WO2004084865A1 (en) 2004-10-07

Family

ID=20290786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/000860 WO2004084865A1 (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof

Country Status (13)

Country Link
EP (1) EP1605921A1 (ja)
JP (2) JP2006521348A (ja)
CN (1) CN1764440A (ja)
AR (1) AR043772A1 (ja)
AU (1) AU2004224557B2 (ja)
BR (1) BRPI0408655A (ja)
CA (1) CA2519155A1 (ja)
CL (1) CL2004000564A1 (ja)
MX (1) MXPA05010196A (ja)
SE (1) SE0300831D0 (ja)
TW (1) TW200503782A (ja)
WO (1) WO2004084865A1 (ja)
ZA (1) ZA200507719B (ja)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502984A (ja) * 2005-08-02 2009-01-29 ドロサファーム アクチェンゲゼルシャフト インドメタシン及び／又はアセメタシンを含む医薬組成物
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8900645B2 (en) 2007-06-13 2014-12-02 Otsuka Pharmaceuticals Co., Ltd. Equol-containing extract, method for production thereof, method for extraction of equol, and equol-containing food
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
US8951555B1 (en) 2000-10-30 2015-02-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8975273B2 (en) 1999-10-29 2015-03-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2015189726A1 (en) * 2014-06-10 2015-12-17 Capsugel Belgium Nv Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use
US9974751B2 (en) 2006-09-15 2018-05-22 Cima Labs Inc. Abuse resistant drug formulation
US10166187B2 (en) 2013-03-06 2019-01-01 Capsugel Belgium Nv Curcumin solid lipid particles and methods for their preparation and use
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2019166098A1 (de) * 2018-03-01 2019-09-06 Lts Lohmann Therapie-Systeme Ag Orale darreichungsform mit theobrominfreiem kakao
US11324699B2 (en) 2014-12-04 2022-05-10 Capsugel Belgium Nv Lipid multiparticulate formulations
US11331268B2 (en) 2016-11-18 2022-05-17 The University Of Western Australia Taste masking product

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101444273B (zh) * 2007-11-22 2013-04-24 何煜 一种保健品口腔速释制剂及其制造方法
WO2009070978A1 (fr) * 2007-11-22 2009-06-11 Yu He Libération rapide dans la cavité buccale des produits de santé et procédé de préparation associé
CN101439053A (zh) * 2007-11-22 2009-05-27 何煜 一种中药口腔速释制剂及其制造方法
BRPI1012170A2 (pt) * 2009-05-20 2016-03-29 Lingual Consegna Pty Ltd formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido.
CN103583781B (zh) * 2013-11-01 2015-11-25 阳波 咖啡味甲硝唑口香糖
JP6334482B2 (ja) * 2015-08-28 2018-05-30 中野Ｂｃ株式会社 固形剤とその製造方法
CA3176596A1 (en) * 2015-12-09 2017-06-15 Poviva Corp. Methods for formulating orally ingestible compositions comprising lipophilic active agents
US20180116240A1 (en) * 2015-12-09 2018-05-03 Poviva Tea, Llc Stable ready-to-drink beverage compositions comprising lipophilic active agents
CN109053718B (zh) * 2018-08-09 2022-06-03 天津理工大学 一种罗格列酮糖精盐及其制备方法
CN111729087A (zh) * 2020-07-24 2020-10-02 成都大学 一种选择性β2受体激动剂的脂质修饰物及其制备方法与用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB785574A (en) * 1955-03-29 1957-10-30 Pfizer & Co C Pharmaceutical compositions containing tetracycline antibiotics
GB918955A (en) * 1960-05-19 1963-02-20 Thomae Gmbh Dr K Pharmaceutical laxative compositions comprising 4,4-dihydroxy-2-amino triphenylmethane
FR2717387A1 (fr) * 1994-03-17 1995-09-22 Hi Pharmtech Procédé de fabrication de comprimés à croquer à base de troxérutine, de carbonate de calcium, de phosphate de calcium, d'aspartate d'arginine, de glutamate d'arginine d'amoxicilline.
WO2000030641A1 (en) * 1998-11-23 2000-06-02 Pharmacia & Upjohn Ab Nicotine-containing pharmaceutical compositions giving a rapid transmucosal absorption
JP2001114668A (ja) * 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd チョコレート剤
JP2002193839A (ja) * 2000-12-27 2002-07-10 Meiji Seika Kaisha Ltd ココア製剤
WO2003026655A1 (en) * 2001-09-27 2003-04-03 Pharmacia Ab New formulations and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001106641A (ja) * 1999-10-06 2001-04-17 Tendou Seiyaku Kk 口内薬
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB785574A (en) * 1955-03-29 1957-10-30 Pfizer & Co C Pharmaceutical compositions containing tetracycline antibiotics
GB918955A (en) * 1960-05-19 1963-02-20 Thomae Gmbh Dr K Pharmaceutical laxative compositions comprising 4,4-dihydroxy-2-amino triphenylmethane
FR2717387A1 (fr) * 1994-03-17 1995-09-22 Hi Pharmtech Procédé de fabrication de comprimés à croquer à base de troxérutine, de carbonate de calcium, de phosphate de calcium, d'aspartate d'arginine, de glutamate d'arginine d'amoxicilline.
WO2000030641A1 (en) * 1998-11-23 2000-06-02 Pharmacia & Upjohn Ab Nicotine-containing pharmaceutical compositions giving a rapid transmucosal absorption
JP2001114668A (ja) * 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd チョコレート剤
JP2002193839A (ja) * 2000-12-27 2002-07-10 Meiji Seika Kaisha Ltd ココア製剤
WO2003026655A1 (en) * 2001-09-27 2003-04-03 Pharmacia Ab New formulations and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 10 July 2002 (2002-07-10), ISHIKURA, TOYOAKI ET AL: "Cocoa powder-containing pharmaceutical formulations", XP002289559, retrieved from STN Database accession no. 2002:513067 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 25 April 2001 (2001-04-25), ISHIKURA, TOYOAKI ET AL: "Pharmaceutical chocolate preparations using cocoa butter substitutes", XP002289558, retrieved from STN Database accession no. 2001:290825 *
See also references of EP1605921A1 *

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278074B2 (en) 1999-10-29 2016-03-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9320717B2 (en) 1999-10-29 2016-04-26 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10076516B2 (en) 1999-10-29 2018-09-18 Purdue Pharma L.P. Methods of manufacturing oral dosage forms
US9675611B1 (en) 1999-10-29 2017-06-13 Purdue Pharma L.P. Methods of providing analgesia
US9669022B2 (en) 1999-10-29 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9669024B2 (en) 1999-10-29 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9056107B1 (en) 1999-10-29 2015-06-16 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8975273B2 (en) 1999-10-29 2015-03-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8980291B2 (en) 1999-10-29 2015-03-17 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9682077B2 (en) 2000-10-30 2017-06-20 Purdue Pharma L.P. Methods of providing analgesia
US9023401B1 (en) 2000-10-30 2015-05-05 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8951555B1 (en) 2000-10-30 2015-02-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9056052B1 (en) 2000-10-30 2015-06-16 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9060940B2 (en) 2000-10-30 2015-06-23 Purdue Pharma L.P. Controlled release hydrocodone
US10022368B2 (en) 2000-10-30 2018-07-17 Purdue Pharma L.P. Methods of manufacturing oral formulations
US9669023B2 (en) 2000-10-30 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9289391B2 (en) 2000-10-30 2016-03-22 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9572804B2 (en) 2000-10-30 2017-02-21 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9198863B2 (en) 2000-10-30 2015-12-01 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9572805B2 (en) 2000-10-30 2017-02-21 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9205056B2 (en) 2000-10-30 2015-12-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9526724B2 (en) 2000-10-30 2016-12-27 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9517236B2 (en) 2000-10-30 2016-12-13 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9205055B2 (en) 2000-10-30 2015-12-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9504681B2 (en) 2000-10-30 2016-11-29 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP2009502984A (ja) * 2005-08-02 2009-01-29 ドロサファーム アクチェンゲゼルシャフト インドメタシン及び／又はアセメタシンを含む医薬組成物
US9216176B2 (en) 2006-09-15 2015-12-22 Cima Labs Inc. Abuse resistant drug formulation
US9572803B2 (en) 2006-09-15 2017-02-21 Cima Labs Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US9974751B2 (en) 2006-09-15 2018-05-22 Cima Labs Inc. Abuse resistant drug formulation
US8900645B2 (en) 2007-06-13 2014-12-02 Otsuka Pharmaceuticals Co., Ltd. Equol-containing extract, method for production thereof, method for extraction of equol, and equol-containing food
US10681930B2 (en) 2007-06-13 2020-06-16 Otsuka Pharmaceutical Co., Ltd. Equol-containing extract, method for production thereof, method for extraction of equol, and equol-containing food
US8993014B2 (en) 2007-06-13 2015-03-31 Otsuka Pharmaceutical Co., Ltd. Equol-containing extract, method for production thereof, method for extraction of equol, and equol-containing food
US9192185B2 (en) 2007-06-13 2015-11-24 Otsuka Pharmaceutical Co., Ltd. Equol-containing extract, method for production thereof, method for extraction of equol, and equol-containing food
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8314083B2 (en) 2009-07-03 2012-11-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US9161902B2 (en) 2009-07-03 2015-10-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US9119771B2 (en) 2009-07-03 2015-09-01 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US9180090B2 (en) 2009-07-03 2015-11-10 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
US10166187B2 (en) 2013-03-06 2019-01-01 Capsugel Belgium Nv Curcumin solid lipid particles and methods for their preparation and use
WO2015189726A1 (en) * 2014-06-10 2015-12-17 Capsugel Belgium Nv Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use
EP3766480A1 (en) * 2014-06-10 2021-01-20 Capsugel Belgium NV Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use
US11324699B2 (en) 2014-12-04 2022-05-10 Capsugel Belgium Nv Lipid multiparticulate formulations
US11331268B2 (en) 2016-11-18 2022-05-17 The University Of Western Australia Taste masking product
WO2019166098A1 (de) * 2018-03-01 2019-09-06 Lts Lohmann Therapie-Systeme Ag Orale darreichungsform mit theobrominfreiem kakao
US20210000963A1 (en) * 2018-03-01 2021-01-07 Lts Lohmann Therapie-Systeme Ag Oral dosage form containing theobromine-free cocoa

Also Published As

Publication number Publication date
MXPA05010196A (es) 2005-11-08
JP2011079841A (ja) 2011-04-21
SE0300831D0 (sv) 2003-03-26
BRPI0408655A (pt) 2006-03-28
AU2004224557B2 (en) 2009-06-18
CA2519155A1 (en) 2004-10-07
ZA200507719B (en) 2007-09-26
AR043772A1 (es) 2005-08-10
JP2006521348A (ja) 2006-09-21
CN1764440A (zh) 2006-04-26
CL2004000564A1 (es) 2005-02-04
EP1605921A1 (en) 2005-12-21
TW200503782A (en) 2005-02-01
AU2004224557A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
AU2004224557B2 (en) Formulations comprising an active ingredient and cocoa powder and use thereof
AU2002334522B2 (en) New formulations and use thereof
US20100197742A1 (en) New formulations and use thereof
JP2002530335A (ja) 急速経粘膜吸収を与えるニコチン含有医薬組成物
AU2002334522A1 (en) New formulations and use thereof
US20100069397A1 (en) Sexual dysfunction compounds
CN1674866B (zh) 含有治疗性功能障碍化合物和可可粉的药物制剂及其用途
CN100548281C (zh) 用于递送催眠药穿过口腔粘膜的组合物及其用法
ZA200506710B (en) Formulations comprising tolterodine and cocoa powder and use thereof
US20040191345A1 (en) New formulations and use thereof
KR20050047527A (ko) 코코아 분말을 포함하는, 신속하게 발현되는 신규성적-기능장애-화합물-함유 제약 제제 및 그의 용도

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004224557

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004720946

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3884/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2519155

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004224557

Country of ref document: AU

Date of ref document: 20040316

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004224557

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20048077898

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2005/07719

Country of ref document: ZA

Ref document number: PA/a/2005/010196

Country of ref document: MX

Ref document number: 200507719

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2006506377

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004720946

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408655

Country of ref document: BR